Compare TTE & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTE | BMY |
|---|---|---|
| Founded | 1924 | 1887 |
| Country | France | United States |
| Employees | 101513 | 32500 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.0B | 123.7B |
| IPO Year | N/A | N/A |
| Metric | TTE | BMY |
|---|---|---|
| Price | $90.70 | $58.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 16 |
| Target Price | ★ $72.56 | $62.13 |
| AVG Volume (30 Days) | 2.4M | ★ 9.4M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.39% | 4.35% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $12.60 | $17.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $56.31 | $42.52 |
| 52 Week High | $93.49 | $62.89 |
| Indicator | TTE | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 56.62 | 49.65 |
| Support Level | $59.88 | $56.45 |
| Resistance Level | $92.34 | $62.39 |
| Average True Range (ATR) | 2.20 | 1.25 |
| MACD | -0.64 | -0.10 |
| Stochastic Oscillator | 57.21 | 34.07 |
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2025, it produced 1.5 million barrels of liquids and 5.4 billion cubic feet of natural gas per day. At the end of 2025, reserves stood at 11.2 billion barrels of oil equivalent, 55% of which are liquids. During 2025, it had LNG sales of 43.9 million metric tons. The company owns interests in refineries with a capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. At year-end, its gross installed renewable power generation capacity was 34 gigawatts.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.